Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study-Reference-Cited by-同舟云学术

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study

Published:2016-09-08 Issue:1 Volume:20 Page:72-81
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

McElroy Heather J.¹,Roberts Stuart K.²,Thompson Alex J.³,Angus Peter W.⁴,McKenna Sarah Jane⁵,Warren Emma⁶,Musgrave Sharon⁷

Affiliation:

1. Covance (Asia) Pte Ltd, Singapore;

2. The Alfred Hospital and Monash University, Melbourne, Vic, Australia;

3. St Vincent’s Hospital and the University of Melbourne, Melbourne, Vic, Australia;

4. Austin Health and the University of Melbourne, Melbourne, Vic, Australia;

5. Covance Pty Ltd, Sydney, NSW, Australia;

6. HERA Consulting, Sydney, NSW, Australia;

7. AbbVie Pty Ltd, Sydney, NSW, Australia

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1227827

Reference31 articles.

1. World Health Organization. Hepititis C Fact Sheet. Geneva, Switzerland: World Health Organization, 2015. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 9, 2015

2. Hepatitis C virus genotypes in Australia

3. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

4. Predictors of deferral of treatment for hepatitis C infection in Australian clinics

5. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015. Sydney: Kirby Institute, The Universitiy of New South Wales, 2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example;Infectious Diseases and Therapy;2024-03

2. Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound;Medical Journal of Australia;2020-02-24